- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05349877
Eficacia de una intervención breve para mejorar la salud mental de las minorías sexuales y de género: ensayo controlado aleatorio. (ESCREVA-SE)
Eficacia de una intervención de escritura breve, autoguiada y en línea para mejorar los resultados de salud mental entre las minorías sexuales y de género: un ensayo controlado aleatorio.
Experiences of violence, from micro to physical aggressions, have a deleterious impact on mental health. According to the Minority Stress Theory, unfavorable social conditions (such as anticipated and experienced discrimination and internalized homophobia), mediated by resilience strategies, can lead to mental health or illness. Sexual and gender minorities (SGM) face stigma and discrimination aggravating multiple aspects of their lives: from school drop-out to halting health care access. SGM reveal avoiding medical assistance for fear of discrimination while health professionals disclose feeling unprepared to handle SGM health needs. There are two main challenges: 1) developing specific psychological interventions to reduce the impact of stigma and discrimination on SGM' mental health; and 2) training public health professionals to properly address SGM needs. Therefore, the present trial aims to assess the efficacy of a brief, self-guided, on-line, asynchronous and unsupervised psychological intervention in improving SGM' mental health.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brasil, 90619-900
- Pontifícia Universidade Católica do Rio Grande do Sul
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Self-identity as sexual and gender minority.
- Being older than 16 years old.
- Have a stable on-line connection for, at least, 20 minutes in a place where won't be disturbed.
- Reports, in the baseline survey, previous experiences of discrimination, having depression or anxiety symptoms.
- Currently living in Rio Grande do Sul.
Exclusion Criteria:
- Disagrees with the consent form.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Triple
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Expressive writing
Participants will be invited to join three writing activities, lasting 20 minutes daily in D1, D3, and D5 of the same week. For example, to write about a difficult or painful experience related discrimination and their feelings about it. |
Write, continuously for 20 minutes, about deepest emotions and thoughts concerning experiences of minority stress, exploring a particular event and how it has affected the participant. |
|
Experimental: Self-affirmation
Aiming to build self-efficacy, participants will be invite to writing, during 20 minutes daily in D1, D3, and D5 of the same week, a letter to a sexual and gender minority peer suffering from stigma and discrimination. |
Write, continuously for 20 minutes, about values the participant think is important to overcome experiences of minority stress. |
|
Comparador de placebos: Placebo
Participants will be instruct to write about their daily routine, during 20 minutes daily in D1, D3, and D5 of the same week. |
Write, continuously for 20 minutes, about their daily routine, without expressing feelings and deep thoughts about it. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change from baseline depression at 3 and 6 moths after the intervention.
Periodo de tiempo: Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).
|
Assessed using the Center for Epidemiologic Studies - Depression (CES-D). CES-D is composed of 20 items. The final score ranges from 0 to 60 points. Originally, the cutoff point of the CES-D scale to identify the presence of depressive symptoms is equal or higher 16 points. However, when considering Brazilian samples, the cutoff point of equal or higher 12 points was proposed. |
Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).
|
|
Change from baseline anxiety at 1 week, and 3 and 6 moths after the intervention.
Periodo de tiempo: Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).
|
Evaluated using the Generalized Anxiety Disorder 7-item (GAD-7). The GAD-7 consists of 7 questions based in part on the DSM-IV criteria for GAD and reflects the frequency of symptoms during the preceding 2-week period. The GAD-7 requires approximately 1-2 minutes to administer and for each symptom queried provides the following response options: "not at all," "several days," "over half the days" and "nearly every day" and these are scored, respectively, as 0, 1, 2 or 3. A score of 10 or greater on the GAD-7 represents a reasonable cut point for identifying cases of GAD. |
Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).
|
|
Change from baseline social phobia at 1 week, and 3 and 6 moths after the intervention.
Periodo de tiempo: Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).
|
Evaluated using the Social Avoidance and Distress Scale (SADS). SADS is a 28 item true/false scale that measures measures aspects of social anxiety including distress, discomfort, fear and avoidance. A total score on the SADS is obtained based on the answers to the true/false questions. Higher scores indicate greater social anxiety. |
Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).
|
|
Change from baseline post-traumatic stress at 1 week, and 3 and 6 moths after the intervention.
Periodo de tiempo: Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).
|
Post-Traumatic Stress Disorder Checklist - Civilian Version (PCL-C). The PCL-C is a 17-item self-report checklist of PTSD symptoms based closely on the DSM-IV criteria. The score consists in adding up all items from each of the 17 items for a total severity score (range = 17-85). The cut off 17-29 shows little to no severity, 28-29 suggests some PTSD symptom, 30-44 moderate to moderately high severity of PTSD symptoms, and 45-85 high severity of PTSD symptoms. |
Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).
|
|
Change from baseline on suicide ideation at 3 and 6 moths after the intervention.
Periodo de tiempo: Baseline (T0), three months after the intervention (T2), and six the intervention (T3).
|
Patient Health Questionnaire-9 (PHQ-9). The PHQ-9 is a clinically-validated screening tool that healthcare providers use to screen for depression, and also to diagnose and monitor the severity of the condition. A PHQ-9 score total of 0-4 points equals "normal" or minimal depression. Scoring between 5-9 points indicates mild depression, 10-14 points indicates moderate depression, 15-19 points indicates moderately severe depression, and 20 or more points indicates severe depression. |
Baseline (T0), three months after the intervention (T2), and six the intervention (T3).
|
|
Change from baseline on substance use at 3 and 6 moths after the intervention.
Periodo de tiempo: Baseline (T0), three months after the intervention (T2), and six the intervention (T3).
|
Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) is an 8 questions tool that detects substance use and related problems. A 'global continuum of risk score' (or total substance involvement) is calculated by the addition of all items for all substances on the ASSIST and has a maximum score of 208. |
Baseline (T0), three months after the intervention (T2), and six the intervention (T3).
|
|
Change from baseline on sex risk behaviors at 3 and 6 moths after the intervention.
Periodo de tiempo: Baseline (T0), three months after the intervention (T2), and six the intervention (T3).
|
Inquired using yes-no questions concerning unprotected intercourse and multiple sex partners, as well as the Perceived Risk of HIV Scale. Perceived Risk of HIV Scale is a self-report 8-item measure developed to assess how people think and feel about their risk of HIV infection based on their previous sexual behavior and covering several dimensions of perceived HIV risk. Higher scores are associated with a greater number of sex partners, episodes of unprotected sex and having sex while high. |
Baseline (T0), three months after the intervention (T2), and six the intervention (T3).
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change from baseline on resilience at 1 week, and 3 and 6 moths after the intervention.
Periodo de tiempo: Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).
|
Wagnild and Youngs's Resilience Scale that has presented the following scoring for the total score: 25-100 = Very low, 101-115 = Low, 116-130 = On the low end, 131-145 = Moderate, 146-160 = Moderately high, and 161-175 = High. |
Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).
|
|
Change from baseline on self-esteem at 1 week, and 3 and 6 moths after the intervention.
Periodo de tiempo: Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).
|
Rosenberg Self-Esteem Scale. The scale ranges from 0-30. Scores between 15 and 25 are within normal range; scores below 15 suggest low self-esteem. |
Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).
|
Colaboradores e Investigadores
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Trastornos relacionados con el trauma y el estrés
- Desordenes mentales
- Síntomas de comportamiento
- Comportamiento auto agresivo
- Trastornos fóbicos
- Suicidio
- Trastornos de Estrés, Traumáticos
- Comportamiento
- Comportamiento social
- Comportamiento Sexual
- Fobia, Social
- Desórdenes de ansiedad
- Ideación suicida
- Depresión
- Trastornos de estrés postraumático
- Sexo inseguro
- Asunción de riesgos
- Discriminación Social
Otros números de identificación del estudio
- PUCRSBR-10098
- 39059120.0.0000.5336 (Otro identificador: Brazil's Plataforma Brasil CAAE)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .